FAD has been used extensively in breast cancer research as a pharmaceutical inhibitor of aromatase and has been shown to be a reversible competitive inhibitor of aromatase in birds (Elbrecht and Smith 1992), mammals (Steele et al. 1987), and fish (Afonso et al. 1999, 2001). Here, CYP19A1 is linked to breast carcinoma.